Cetera Investment Advisers Purchases 3,121 Shares of Moderna, Inc. (NASDAQ:MRNA)

Cetera Investment Advisers lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 8.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 40,783 shares of the company’s stock after acquiring an additional 3,121 shares during the quarter. Cetera Investment Advisers’ holdings in Moderna were worth $1,696,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in MRNA. Wilmington Savings Fund Society FSB grew its stake in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna in the 4th quarter worth $37,000. Venturi Wealth Management LLC grew its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares in the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Moderna in the 4th quarter worth $41,000. Finally, Itau Unibanco Holding S.A. boosted its holdings in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after buying an additional 343 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 6.1%

Shares of MRNA opened at $27.99 on Wednesday. The business’s 50-day moving average price is $27.70 and its 200-day moving average price is $35.11. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $170.47. The stock has a market cap of $10.82 billion, a PE ratio of -3.02 and a beta of 1.99.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analysts’ expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. Moderna’s revenue for the quarter was down 35.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($3.07) earnings per share. Analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on MRNA shares. Citigroup started coverage on shares of Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price target on the stock. Bank of America cut their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. JPMorgan Chase & Co. cut their price target on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Friday, March 21st. Evercore ISI cut their price target on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating on the stock in a report on Friday, May 2nd. Finally, Barclays dropped their price objective on shares of Moderna from $45.00 to $40.00 and set an “equal weight” rating on the stock in a report on Friday, May 2nd. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $53.95.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.